Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…Abstract Number: 2029 • ACR Convergence 2025
Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Up to one-third of patients experience disease flares in adulthood, with…Abstract Number: 1654 • ACR Convergence 2025
A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts
Background/Purpose: Chronic synovitis is a hallmark of juvenile idiopathic arthritis (JIA), and synovial fibroblasts are major perpetrators of inflammation and tissue destruction. Thus, we tested…Abstract Number: 0419 • ACR Convergence 2025
Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
Background/Purpose: Ultrasound-guided synovial biopsy (USGSB) has been recently implemented for clinical and research purposes in adults with inflammatory arthritis. The current use of USGSB in…Abstract Number: 0400 • ACR Convergence 2025
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…Abstract Number: 1989 • ACR Convergence 2025
Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
Background/Purpose: Young adults with childhood-onset rheumatic conditions encounter challenges and barriers to care when transitioning to an adult rheumatologist. At this Pediatric Rheumatology Clinic, patients…Abstract Number: 1304 • ACR Convergence 2025
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
Background/Purpose: Fever of Unknown Origin (FUO) is a relatively common clinical challenge that is frequently referred for evaluation by pediatric rheumatologists. In many cases, it…Abstract Number: 0418 • ACR Convergence 2025
Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Clinical, radiologic and biomarker data are measurements used in the assessment of juvenile idiopathic arthritis (JIA) disease activity. The development of ultrasound-guided synovial biopsy…Abstract Number: 0399 • ACR Convergence 2025
External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within…Abstract Number: 2680 • ACR Convergence 2025
High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy and improves outcomes, yet JIA patients often experience circuitous pathways to diagnosis.…Abstract Number: 1978 • ACR Convergence 2025
Utilizing a Gap to Target Function in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry Dashboard of Quality Measures
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning health network organized to improve outcomes of juvenile idiopathic arthritis (JIA).…Abstract Number: 1280 • ACR Convergence 2025
Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Background/Purpose: During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims…Abstract Number: 0417 • ACR Convergence 2025
Implementation of a Communication Aid in Juvenile Idiopathic Arthritis Patient Visits, a Quality Improvement Study
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a childhood onset autoimmune disease requiring long-term care and personalized treatment. Through a rigorous series of mixed patient and…Abstract Number: 0398 • ACR Convergence 2025
Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…Abstract Number: 2679 • ACR Convergence 2025
Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort
Background/Purpose: Early-life nutrition may influence the risk of immune-mediated diseases like juvenile idiopathic arthritis (JIA). The benefits of breastfeeding are well established, but findings related…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 25
- Next Page »
